EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 42 / No 3 (Mars 2026) Med Sci (Paris), 42 3 (2026) 295-305 References
Open Access
Issue
Med Sci (Paris)
Volume 42, Number 3, Mars 2026
Page(s) 295 - 305
Section Repères
DOI https://doi.org/10.1051/medsci/2026040
Published online 20 March 2026
  1. Mackey TK, Purushothaman V, Haupt M, et al. Application of unsupervised machine learning to identify and characterise hydroxychloroquine misinformation on Twitter. Lancet Digit Health 2021 ; 3 : e72–5. [Google Scholar]
  2. Molimard M, Costagliola D, Maisonneuve H. Information en santé. Bilan des forces et des faiblesses. Recommandations pour une stratégie nationale d’information et de lutte contre la désinformation en santé. 2026 ; https://sante.gouv.fr/IMG/pdf/rapport_information.pdf. [Google Scholar]
  3. Flay BR. Efficacy and effectiveness trials (and other phases of research) in the development of health promotion programs. Prev Med 1986 ; 15 : 451–74. [Google Scholar]
  4. Selker HP, Eichler H, Stockbridge NL, et al. Efficacy and effectiveness too trials: clinical trial designs to generate evidence on efficacy and on effectiveness in wide practice. Clin Pharmacol Ther 2019 ; 105 : 857–66. [Google Scholar]
  5. Hardelin JP. Facteur « confondant » ou de confusion. Med Sci (Paris) 2024 ; 40 : 381–1. [CrossRef] [EDP Sciences] [Google Scholar]
  6. Sedgwick P. External and internal validity in clinical trials. BMJ 2012 ; 344 : e1004. [Google Scholar]
  7. Collins R, Bowman L, Landray M, et al. The magic of randomization versus the myth of real-world evidence. N Engl J Med 2020 ; 382 : 674–8. [Google Scholar]
  8. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020 ; 383 : 2603–15. [CrossRef] [PubMed] [Google Scholar]
  9. Baden LR, Sahly HME, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2020 ; 384 : 403–16. [Google Scholar]
  10. Société Française de Pharmacologie et de Thérapeutique. Livre blanc. De la nécessité de la méthodologie dans l’évaluation des médicaments. https://sfpt-fr.org/livreblancmethodo/index.htm [Google Scholar]
  11. Hodgson SH, Mansatta K, Mallett G, et al. What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. Lancet Infect Dis 2021 ; 21 : e26–35. [Google Scholar]
  12. Riggs BL, Hodgson SF, O’Fallon WM, et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 1990 ; 322 : 802–9. [Google Scholar]
  13. Sarri G, Patorno E, Yuan H, et al. Framework for the synthesis of non-randomised studies and randomised controlled trials: a guidance on conducting a systematic review and meta-analysis for healthcare decision making. BMJ Evid Based Med 2022 ; 27 : 109–19. [Google Scholar]
  14. Sommet A, Pariente A. Methods in pharmacoepidemiology. Therapie 2019 ; 74 : 187–97. [Google Scholar]
  15. Furukawa TA, Guyatt GH, Griffith LE. Can we individualize the ‘number needed to treat’? An empirical study of summary effect measures in meta-analyses. Int J Epidemiol 2002 ; 31 : 72–6. [Google Scholar]
  16. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 1988 ; 318 : 1728–33. [Google Scholar]
  17. Correia LCL, Matias D. COVID-19 vaccines: effectiveness and number needed to treat. Lancet Microbe 2021 ; 2 : e281. [Google Scholar]
  18. Olliaro P, Torreele E, Vaillant M. COVID-19 vaccine efficacy and effectiveness-the elephant (not) in the room. Lancet Microbe 2021 ; 2 : e279–80. [Google Scholar]
  19. Christensen PM, Kristiansen IS. Number-needed-to-treat (NNT) – needs treatment with care. Basic Clin Pharmacol Toxicol 2006 ; 99 : 12–6. [Google Scholar]
  20. Montastruc J, Biron P, Sommet A. Efficacy of COVID-19 vaccines: Several modes of expression should be presented in scientific publications. Fundam Clin Pharmacol 2022 ; 36 : 218–20. [Google Scholar]
  21. Adams K, Riddles JJ, Rowley EAK, et al. Number needed to vaccinate with a COVID-19 booster to prevent a COVID-19-associated hospitalization during SARS-CoV-2 Omicron BA.1 variant predominance, December 2021-February 2022, VISION Network: a retrospective cohort study. Lancet Reg Health Am 2023 ; 23 : 100530. [Google Scholar]
  22. Thomas SJ, Moreira ED, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 Months. N Engl J Med 2021 ; 383 :2603–15. [Google Scholar]
  23. Feikin DR, Higdon MM, Abu-Raddad LJ, et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet 2022 ; 399 : 924–44. [Google Scholar]
  24. CIOMS Cumulative Glossary, with a focus on Pharmacovigilance (version 2.1). Counc Int Organ Med Sci https://cioms.ch/wpcontent/uploads/2023/04/CIOMSGlossary_v2.1_1stMay2023.pdf [Google Scholar]
  25. The use of the WHO-UMC system for standardised case causality assessment https://www.who.int/docs/default-source/medicines/pharmacovigilance/whocausality-assessment.pdf [Google Scholar]
  26. Miremont-Salamé G, Théophile H, Haramburu F, et al. Causality assessment in pharmacovigilance: the French method and its successive updates. Therapie 2016 ; 71 : 179–86. [Google Scholar]
  27. Onakpoya IJ. Rare adverse events in clinical trials: understanding the rule of three. BMJ Evid Based Med 2018 ; 23 : 6. [Google Scholar]
  28. Berlin JA, Glasser SC, Ellenberg SS. Adverse event detection in drug development: recommendations and obligations beyond phase 3. Am J Public Health 2008 ; 98 : 1366–71. [Google Scholar]
  29. Shimabukuro TT, Cole M, Su JR. Reports of anaphylaxis after receipt of mRNA COVID-19 vaccines in the US-December 14, 2020-January 18, 2021. JAMA 2021 ; 325 : 1101. [CrossRef] [PubMed] [Google Scholar]
  30. Shimabukuro T, Nair N. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 Vaccine. JAMA 2021 ; 325 :780–1. [Google Scholar]
  31. Le Vu S, Bertrand M, Jabagi M-J, et al. Age and sex-specific risks of myocarditis and pericarditis following Covid-19 messenger RNA vaccines. Nat Commun 2022 ; 13 : 3633. [Google Scholar]
  32. Salmon DA, Chen RT, Black S, et al. Lessons learned from COVID-19, H1N1, and routine vaccine pharmacovigilance in the United States: a path to a more robust vaccine safety program. Expert Opin Drug Saf 2024 ; 23 : 161–75. [Google Scholar]
  33. Greinacher A, Thiele T, Warkentin TE, et al. Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. N Engl J Med 2021 ; 384 : 2092–101. [CrossRef] [PubMed] [Google Scholar]
  34. Shimabukuro T. COVID-19 Vaccine safety updates. CDC Gov 2021 ; https://stacks.cdc.gov/view/cdc/108329 [Google Scholar]
  35. Lo CH, Wang YH, Tsai CF, et al. Association of hydroxychloroquine and cardiac arrhythmia in patients with systemic lupus erythematosus: A population-based case control study. PLoS One 2021 ; 16 : e0251918. [Google Scholar]
  36. Axfors C, Schmitt AM, Janiaud P, et al. Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. Nat Commun 2021 ; 12 : 2349. [Google Scholar]
  37. Lemaitre F, Grégoire M, Monchaud C, et al. Management of drug-drug interactions with nirmatrelvir/ritonavir in patients treated for Covid-19: Guidelines from the French Society of Pharmacology and Therapeutics (SFPT). Therapie 2022 ; 77 : 509–21. [Google Scholar]
  38. Bihan K, Lipszyc L, Lemaitre F, et al. Nirmatrelvir/ritonavir (Paxlovid®): French pharmacovigilance survey 2022. Therapie 2023 ; 78 : 531–47. [Google Scholar]
  39. Benefit-risk methodology – European Medicines Agency. https://www.ema.europa.eu/en/documents/report/benefit-risk-methodology-project-work-package-2-report-applicability-current-tools-and-processes-regulatory-benefit-risk-assessment_en.pdf [Google Scholar]
  40. Benefit-Risk Assessment for New Drug and Biological Products. 2023. https://www.fda.gov/ regulatory-information/search-fda-guidance-documents/benefit-risk-assessment-new-drug-and-biological-products [Google Scholar]
  41. Covid-19. Dr Chris Cates’ EBM Website 2020. https://www.nntonline.net/topics/covid-19/ [Google Scholar]
  42. European Medicines Agency. Annex to Vaxzevria Art.5.3 – Visual risk contextualisation. https://www.ema.europa.eu/en/documents/chmp-annex/annex-vaxzevria-art53-visual-risk-contextualisation_en.pdf [Google Scholar]
  43. Bozkurt B, Kamat I, Hotez PJ. Myocarditis with COVID-19 mRNA vaccines. Circulation 2021 ; 144 : 471–84. [Google Scholar]
  44. Buyse M, Saad ED, Peron J, et al. The net benefit of a treatment should take the correlation between benefits and harms into account. J Clin Epidemiol 2021 ; 137 : 148–58. [Google Scholar]
  45. Pocock SJ, Ariti CA, Collier TJ, et al. The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities. Eur Heart J 2012 ; 33 : 176–82. [Google Scholar]
  46. Chou WYS, Oh A, Klein WMP. Addressing health-related misinformation on social media. JAMA 2018 ; 320 : 2417–8. [CrossRef] [PubMed] [Google Scholar]
  47. Larrouquere L, Gabin M, Poingt E, et al. Genesis of an emergency public drug information website by the French society of pharmacology and therapeutics during the COVID-19 pandemic. Fundam Clin Pharmacol 2020 ; 34 : 389–96. [Google Scholar]
  48. Ward JK, Gauna F, Gagneux-Brunon A, et al. The French health pass holds lessons for mandatory COVID-19 vaccination. Nat Med 2022 ; 28 : 232–5. [Google Scholar]
  49. Khouri C, Larabi A, Verger P, et al. Impact of vaccine hesitancy on onset, severity and type of self-reported adverse events: a french cross-sectional survey. Drug Saf 2022 ; 45 : 1049–56. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.